Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats

Inflammation Research

Volumn 49, Issue 8, 2000, Pages 404-410

  Matsuura, M ^a   Imayoshi, T ^a   Chiba, K ^a   Okumoto, T ^a  

^a Welfide Corporation   (Japan)

Author keywords

Adjuvant induced arthritis; Cyclosporin A; FTY720; Peripheral lymphocyte; Tracrolimus

Indexed keywords

CYCLOSPORIN A; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; OLIVE OIL; TACROLIMUS;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEFECT; BONE RADIOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PAW EDEMA; PLETHYSMOGRAPHY; RAT;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CYCLOSPORINE; EDEMA; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHILS; OSTEOLYSIS; PROPYLENE GLYCOLS; RATS; RATS, INBRED LEW; SPHINGOSINE; TACROLIMUS;

EID: 0033829476     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050608     Document Type: Article

References (29)

1. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes
2. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis
3. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporin with placebo. Norwegian Arthritis Study Group
4. FK506 in the treatment of psoriasis and psoriatic arthritis
5. FK506 in the treatment of polymyositis
6. FK506 in severe treatment resistant juvenile rheumatoid arthritis (JRA)
7. FK506 in severe treatment resistant juvenile rheumatoid arthritis (JRA)
8. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases
9. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing
10. Design synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720
11. FTY720 a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats
12. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A
13. FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporin A
14. FTY720, a novel immunosuppressant, possessing unique mechanisms. IV. Prevention of graft versus host reactions in rats
15. Histopathologic evaluation of the effects of etodolac in established adjuvant arthritis in rats: Evidence for reversal of joint damage
16. Meloxicam: A potent inhibitor of adjuvant arthritis in the Lewis rat
17. Monoclonal antibodies and arthritis
18. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo
19. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation
20. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes
21. Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: The regulation of lymph node cell populations and cytokine production
22. Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor
23. Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti CD2 monoclonal antibody (mAb) OX34
24. Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis
25. Cellular adhesion molecules in rat adjuvant arthritis
26. Changes in vascular endothelium related to lymphocyte collections in diseased synovia
27. The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium
28. Electron microscopic study of rheumatoid synovial vasculature. Intimate relationship between tall endothelium and lymphoid aggregation
29. A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium